Intracoronary administration of a miR-452-5p inhibitor improved diastolic relaxation, cardiac remodeling, subendocardial microvascular density, and cardiac VEGF expression in a swine model of CKM.
Does targeted inhibition of miR-452-5p improve cardiac hemodynamics and microvascular rarefaction in a swine model of CKM syndrome?
Targeted intracoronary inhibition of miR-452-5p rescues cardiac VEGF signaling and improves cardiac hemodynamics and microvascular integrity in a swine model of CKM syndrome.
Background: Cardiovascular-Kidney-Metabolic (CKM) syndrome entails pathophysiological interactions leading to multiorgan dysfunction and a high rate of cardiovascular morbidity and mortality, largely driven by the development of heart failure (HF). Mechanisms leading to HF in CKM syndrome are unknown. We created a model of CKM syndrome in swine and showed that cardiac abnormalities associate with cardiac microvascular (MV) rarefaction and decreased expression and availability of VEGF. Emerging research focuses on micro-RNAs (miRNAs) and their role in the pathophysiology of HF, but whether they play a role in the development of cardiac injury in CKM syndrome via VEGF modulation has not been investigated. We aimed to identify specific miRNAs that can target VEGF to test the hypothesis that their direct cardiac inhibition will rescue cardiac VEGF, improve angiogenic signaling, and cardiac hemodynamics in CKM syndrome. Methods: CKM (bilateral renal artery stenosis+high-cholesterol/high-carbohydrate feeding) and normal pigs (n=4 each, 2 males/2 females) were studied for 14 weeks. Unbiased micro-RNA sequencing identified 26 miRNAs differentially expressed in CKM pig hearts, of which only miR-452-5p can target VEGFA, which was confirmed by pulldown analysis and qPCR. In addition, CKM (n=4, 2 males/2 females) were treated after 6 weeks with a single intracoronary (IC) administration of a miR-452-5p inhibitor (antagomiR). Cardiac hemodynamics (echocardiography), MV architecture (3D micro-CT) and cardiac expression of VEGF and miR-452-5p (RT-qPCR) were quantified before IC miR-452-5p inhibition, and again at the end of the study (14 weeks). Results: Pigs with CKM syndrome showed blunted diastolic relaxation, increased cardiac remodeling, and reduced subendocardial MV density and cardiac VEGF expression, accompanied by higher cardiac expression of miR-452-5p compared to normal pigs. Notably, most of these parameters were improved after in vivo IC miR-452-5p inhibition (single dose). Blood pressure was unchanged ( Table 1 ). Conclusions: Our study supports a role for VEGF in preserving cardiac MV integrity in CKM syndrome. Also, it identifies a targeted post-transcriptional regulation of VEGF via miR-452-5p and supports the feasibility and efficacy of its mechanistic modulation in vivo. The predictive power of our model conceptually supports the potential of a novel targeted intervention to protect the heart in CKM syndrome. Table: see text Support: NIH AG084154 (ARC), and DK129240 (AE) This abstract was presented at the American Physiology Summit 2026 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
MARTIN et al. (Fri,) conducted a other in Cardiovascular-Kidney-Metabolic (CKM) syndrome (n=12). miR-452-5p inhibitor (antagomiR) vs. untreated CKM pigs and normal pigs was evaluated on Cardiac hemodynamics, microvascular architecture, and cardiac expression of VEGF and miR-452-5p. Intracoronary administration of a miR-452-5p inhibitor improved diastolic relaxation, cardiac remodeling, subendocardial microvascular density, and cardiac VEGF expression in a swine model of CKM.